1-3 of 3
Martin Zeier
Close
Sort by
Journal Articles

Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion — a Phase I Study (TOL-1)

Christian Morath, MD, Anita Schmitt, MD, Christian Kleist, PhD, Volker Daniel, MD, Gerhard Opelz, MD, Caner Süsal, MD, Florian Kälble, MD, Claudia Sommerer, MD, Lei Wang, MD, Angela Hückelhoven, PhD, Arianeb Mehrabi, MD, Uta Merle, MD, Luiza Pego da Silva, Carsten Müller-Tidow, MD, Martin Zeier, MD, Matthias Schaier, MD, Michael Schmitt, MD PhD, Peter Terness, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4539.
https://doi.org/10.1182/blood-2018-99-113386
Published: 2018
Journal Articles

Development of Potency Assays for Quality Assessment of an Advanced Therapy Medicinal Product: Mitomycin C-Induced Peripheral Blood Mononuclear Cell (MIC) Product

Ming NI, Lei Wang, MD, Christian Kleist, PhD, Peter Terness, MD, Gerhard Opelz, MD, Christian Morath, MD, Matthias Schaier, MD, Carsten Müller-Tidow, MD, Martin Zeier, MD, Michael Schmitt, MD PhD, Anita Schmitt, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5689.
https://doi.org/10.1182/blood-2018-99-113337
Published: 2018
Journal Articles

Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis.

Stefan Schonland, Ute Hegenbart, MD, Axel Benner, Jolanta Perz, Tilmann Bochtler, Jörg Beimler, Martin Zeier, Arnt Kristen, Anthony D. Ho, MD, PhD, Hartmut Goldschmidt
Journal: Blood
Blood (2009) 114 (22): 3401.
https://doi.org/10.1182/blood.V114.22.3401.3401
Published: 2009